Pharmaceuticals News and Research

RSS

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

Sagent Pharmaceuticals introduces pamidronate disodium injection in single-dose vials

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL. Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor. The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.

20 Jan 2010

LEO Pharma launches psoriasis franchise in the U.S.

Denmark-based LEO Pharma, a global leader in dermatology and critical care, announced its official launch in the U.S. Headquartered in Parsippany, New Jersey, LEO Pharma U.S. will be one of the largest individual operations in the pharmaceutical company’s network of worldwide affiliates and is expected to contribute significantly to the company revenues in 2010.

20 Jan 2010

Liquidia Technologies completes $20M Series C financing round

Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, today announced it has completed a $20 million round of Series C financing. Canaan Partners led the Series C round, which also included Pappas Ventures and Morningside Venture Investments Limited as new investors. Previous investors, including New Enterprise Associates and Firelake Capital, also participated in the financing round.

20 Jan 2010

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

Oramed Pharmaceuticals Inc. announced today the completion of patient enrollment in the Phase 2B clinical study of its oral insulin capsule, ORMD-0801.

20 Jan 2010

Fraunhofer USA CMB receives $60,000 gift from ProTecs to complete vaccine manufacturing plant

The Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, 501 (c3) research organization, announced today that it has received a $60,000 gift from ProTecs, Inc., to complete its new, state of-the-art vaccine manufacturing plant in Newark, Delaware.

20 Jan 2010

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

20 Jan 2010

Health insurer stocks rise as Wall Street anticipates Republican victory in Mass.

"Health insurer shares rose on Tuesday, while hospital stocks fell as investors anticipated a Republican victory in the special Massachusetts election for a new U.S. senator that would throw healthcare reform into uncertainty," Reuters reports. "The Street prefers a simple narrative," said Les Funtleyder, a health care analyst with Miller Tabak. "The narrative is Coakley in Massachusetts is in trouble and therefore the healthcare reform bill is also in trouble" (Krauskopf, 1/19).

19 Jan 2010

China Pediatric Pharmaceuticals applies for listing on NASDAQ

China Pediatric Pharmaceuticals, Inc., today announced it has applied for listing approval on the NASDAQ Capital Market (“NASDAQ”).

19 Jan 2010

Watson Laboratories files ANDA for Lidoderm

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lidocaine topical patch 8% prior to the expiration of U.S. Patent No. 5,827,529.

19 Jan 2010

WHO, CDC issue H1N1 updates

Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.

19 Jan 2010

Thermo Fisher Scientific signs definitive agreement to acquire Ahura Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has signed a definitive agreement to acquire Ahura Scientific, a leader in field-deployed analytical instruments for human health and public safety, for $145 million in cash plus the potential for an earn-out payment based on the achievement of certain 2010 financial targets.

From Thermo Fisher Scientific Inc. 19 Jan 2010

Titan Pharmaceuticals files registration statement on Form 10 with SEC

Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) today announced that on January 14, 2010 it filed a registration statement on Form 10 with the U.S. Securities and Exchange Commission ("SEC") in order to register its common stock under the Securities Exchange Act of 1934 ("Exchange Act").

19 Jan 2010

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

19 Jan 2010

EMBL-EBI hosts drug discovery database

ChEMBLdb, a vast online database of information on the properties and activities of drugs and drug-like small molecules and their targets, launches today with information on over half a million compounds. The data lie at the heart of translating information from the human genome into successful new drugs in the clinic.

19 Jan 2010

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.

19 Jan 2010

Abbott to provide critical pharmaceutical and nutritional products for Haiti relief efforts

Working directly with humanitarian partners to help address the growing health care crisis, Abbott is expanding its support for relief efforts in Haiti. The company will provide $2.5 million in grant funding and donations of critical pharmaceutical and nutritional products to humanitarian aid organizations.

19 Jan 2010

CSafe and AcuTemp Thermal Systems offer temperature controlled containers for the Haitian relief effort

AcuTemp Thermal Systems, www.acutemp.com, a manufacturer of active and passive containers for transporting temperature sensitive pharmaceutical and bio-medical products; and CSafe, LLC, www.csafellc.com, a provider of active container solutions for the temperature sensitive airfreight market, are offering relief agencies their temperature controlled containers for use in shipping and storing blood, vaccines and other critical temperature sensitive medical supplies for the Haitian relief effort.

19 Jan 2010

Enrollment of Phase 2 portion of Cempra Pharmaceuticals' Phase 2/3 clinical trial of TAKSTA completed

Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.

19 Jan 2010

Calsed earns proprietary clinical gold standard status from Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene/Nippon Kayaku's Calsed earns Decision Resources' proprietary clinical gold standard status in 2013 for the treatment of extensive-disease small-cell lung cancer, following its approval for the indication in 2012.

19 Jan 2010

Pharmaceuticals News and Research

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Sagent Pharmaceuticals introduces pamidronate disodium injection in single-dose vials

LEO Pharma launches psoriasis franchise in the U.S.

Liquidia Technologies completes $20M Series C financing round

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

Fraunhofer USA CMB receives $60,000 gift from ProTecs to complete vaccine manufacturing plant

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Health insurer stocks rise as Wall Street anticipates Republican victory in Mass.

China Pediatric Pharmaceuticals applies for listing on NASDAQ

Watson Laboratories files ANDA for Lidoderm

WHO, CDC issue H1N1 updates

Thermo Fisher Scientific signs definitive agreement to acquire Ahura Scientific

Titan Pharmaceuticals files registration statement on Form 10 with SEC

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

EMBL-EBI hosts drug discovery database

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

Abbott to provide critical pharmaceutical and nutritional products for Haiti relief efforts

CSafe and AcuTemp Thermal Systems offer temperature controlled containers for the Haitian relief effort

Enrollment of Phase 2 portion of Cempra Pharmaceuticals' Phase 2/3 clinical trial of TAKSTA completed

Calsed earns proprietary clinical gold standard status from Decision Resources

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence